Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Colombel, Jean-Frédéric"" wg kryterium: Autor


Tytuł :
Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Autorzy :
Fenster M; Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Ungaro RC; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Hirten R; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Gallinger Z; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada.
Cohen L; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Atreja A; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Mehandru S; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Cohen BL; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: .
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2020 Jan; Vol. 18 (1), pp. 257-258. Date of Electronic Publication: 2019 Mar 22.
Typ publikacji :
Comparative Study; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Outpatient Clinics, Hospital*/statistics & numerical data
Antibodies, Monoclonal, Humanized/*administration & dosage
Biological Factors/*administration & dosage
Home Care Services/*statistics & numerical data
Inflammatory Bowel Diseases/*drug therapy
Infliximab/*administration & dosage
Antibodies, Monoclonal, Humanized/adverse effects ; Biological Factors/adverse effects ; Emergency Service, Hospital/statistics & numerical data ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Hospitalization/statistics & numerical data ; Humans ; Inflammatory Bowel Diseases/epidemiology ; Infliximab/adverse effects ; Infusions, Intravenous ; Monitoring, Physiologic ; Retrospective Studies ; Withholding Treatment/statistics & numerical data
Raport
Tytuł :
Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Autorzy :
Panés J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindsay JO; Department of Gastrointestinal and Liver Services, Royal London Hospital, Barts Health NHS Trust, London, UK.
Teich N; Innere Medizin/Gastroenterologie, Internistische Gemeinschaftspraxis, Leipzig, Germany.
Lindgren S; Department of Gastroenterology, Lund University, Malmo, Sweden.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Flynn HA; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Huyck S; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Stryszak P; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Yao R; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Philip G; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Universitätsklinik für Innere Medizin III, Vienna, Austria.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1148-1157.
Typ publikacji :
Comparative Study; Journal Article; Observational Study
MeSH Terms :
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adrenal Cortex Hormones/therapeutic use ; Adult ; Europe ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Immunosuppressive Agents/therapeutic use ; Infections/chemically induced ; Infliximab/adverse effects ; Male ; Product Surveillance, Postmarketing ; Prospective Studies ; Registries
Czasopismo naukowe
Tytuł :
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Autorzy :
Colombel JF; Department of Gastroenterology, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Adedokun OJ; Janssen Research & Development, Spring House, Pennsylvania.
Gasink C; Janssen Scientific Affairs, Horsham, Pennsylvania.
Gao LL; Janssen Scientific Affairs, Horsham, Pennsylvania.
Cornillie FJ; MSD International, Kriens, Switzerland.
D'Haens GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Rutgeerts PJ; Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Reinisch W; Universitätsklinik für Innere Medizin III, Vienna, Austria.
Sandborn WJ; Division of Gastroenterology and Department of Medicine, University of California, San Diego, San Diego, California.
Hanauer SB; Department of Medicine, Digestive Health Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2019 Jul; Vol. 17 (8), pp. 1525-1532.e1. Date of Electronic Publication: 2018 Sep 26.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Azathioprine/*pharmacokinetics
Crohn Disease/*drug therapy
Infliximab/*pharmacokinetics
Remission Induction/*methods
Adult ; Crohn Disease/blood ; Drug Therapy, Combination ; Female ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Autorzy :
Boyapati RK; Department of Gastroenterology, Monash Health, Clayton, Victoria, Australia.
Torres J
Palmela C
Parker CE
Silverberg OM
Upadhyaya SD
Nguyen TM
Colombel JF
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2018 May 12; Vol. 5. Cochrane AN: CD012540. Date of Electronic Publication: 2018 May 12.
Typ publikacji :
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms :
Withholding Treatment*
Azathioprine/*therapeutic use
Crohn Disease/*therapy
Gastrointestinal Agents/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Infliximab/*therapeutic use
Adult ; Combined Modality Therapy/methods ; Crohn Disease/complications ; Crohn Disease/drug therapy ; Feasibility Studies ; Humans ; Randomized Controlled Trials as Topic ; Recurrence ; Remission Induction ; Secondary Prevention/methods
Czasopismo naukowe
Tytuł :
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission.
Autorzy :
Reenaers C; Gastroenterology Department, Centre Hospitalier Universitaire de Liège, Liège, Belgium. Electronic address: .
Mary JY; INSERM U717, Biostatistics and Clinical Epidemiology, Université Paris Diderot-Paris 7, Paris, France.
Nachury M; Centre Hospitalier Régional Universitaire de Lille, Université Lille Nord de France, Lille, France.
Bouhnik Y; Hôpital Beaujon, Université Paris Diderot-Paris 7, Paris, France.
Laharie D; Hôpital Haut-Lévêque, INSERM U853, Université Bordeaux 2, Bordeaux, France.
Allez M; Hôpital Saint-Louis, Université Paris Diderot-Paris 7, Paris, France.
Fumery M; Centre Hospitalier Universitaire d'Amiens, Hôpital Nord, Amiens, France.
Amiot A; Hôpital Henri Mondor, Paris Est-Créteil Val de Marne University, Creteil, France.
Savoye G; Hôpital Charles Nicolle, Université de Rouen, Rouen, France.
Altwegg R; Hôpital Saint-Eloi, University Hospital of Montpellier, Montpellier, France.
Devos M; Faculty of Medicine and Health Science, University of Ghent, Ghent, Belgium.
Malamut G; Hôpital Européen Georges Pompidou Assistance Publique-Hôpitaux Paris, Université Paris Descartes-Sorbonne Paris Centre, Paris, France.
Bourreille A; Centre Hospitalier Universitaire de Nantes, Hôtel-Dieu, Nantes, France.
Flourie B; Centre Hospitalo-Universitaire Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Marteau P; Hôpital Lariboisière, Assistance Publique-Hôpitaux Paris, University Denis Diderot, Paris, France.
Vuitton L; Hôpital Universitaire de Besançon, Besançon, France.
Coffin B; Hopital Louis Mourier, Université Paris Diderot-Paris 7, Paris, France.
Viennot S; Hôpital Universitaire de Caen, Caen, France.
Lambert J; INSERM U717, Biostatistics and Clinical Epidemiology, Université Paris Diderot-Paris 7, Paris, France.
Colombel JF; Icahn School of Medicine at Mount Sinai, Feinstein Inflammatory Bowel Disease Clinical Center, New York, New York.
Louis E; Gastroenterology Department, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
Pokaż więcej
Corporate Authors :
Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2018 Feb; Vol. 16 (2), pp. 234-243.e2. Date of Electronic Publication: 2017 Oct 07.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Crohn Disease/*drug therapy
Crohn Disease/*pathology
Gastrointestinal Agents/*administration & dosage
Infliximab/*administration & dosage
Adult ; Belgium ; Female ; Follow-Up Studies ; France ; Humans ; Male ; Prospective Studies ; Recurrence ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Autorzy :
D'Haens G; Department of Gastroenterology, Academic MedicalCenter, Amsterdam, The Netherlands.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Medical University, Vienna, Austria and McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Ghosh S; Department of Gastroenterology, University of Calgary, Calgary, AB, Canada.
Prantera C; Department of Gastroenterology, A.O. San Camillo Forlanini, Rome, Italy.
Lindgren S; Department of Gastroenterology, Lund University, University Hospital Skane, Malmö, Sweden.
Hommes DW; Centre for Inflammatory Bowel Diseases, Univerisity of California Los Angeles, Los Angeles, CA, USA.
Huang Z; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Boice J; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Huyck S; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International GmbH, Lucerne, Switzerland.
Pokaż więcej
Corporate Authors :
ENCORE investigators
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jun 01; Vol. 11 (6), pp. 680-689.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Crohn Disease/*drug therapy
Gastrointestinal Agents/*adverse effects
Hematologic Diseases/*chemically induced
Infections/*chemically induced
Infliximab/*adverse effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents/adverse effects ; Azathioprine/adverse effects ; Demyelinating Diseases/chemically induced ; Drug Substitution ; Drug Therapy, Combination/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infusions, Intravenous/adverse effects ; Lymphoproliferative Disorders/chemically induced ; Male ; Mercaptopurine/adverse effects ; Mesalamine/adverse effects ; Methotrexate/adverse effects ; Middle Aged ; Mortality ; Narcotics/adverse effects ; Prednisone/adverse effects ; Prospective Studies ; Registries ; Risk Factors ; Sulfasalazine/adverse effects ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
Autorzy :
Collins M; Gastroenterology and Hepatology Department, Lille University Hospital, Lille, France.; Gastroenterology Department, Kremlin-Bicêtre University Hospital, Le Kremlin-Bicêtre, France.
Sarter H; Lille Inflammation Research International Center, Université Lille, CHRU de Lille, France.
Gower-Rousseau C; Lille Inflammation Research International Center, Université Lille, CHRU de Lille, France.
Koriche D; Colorectal Surgery Department, Lille University Hospital, Lille, France.
Libier L; Gastroenterology and Hepatology Department, Lille University Hospital, Lille, France.
Nachury M; Gastroenterology and Hepatology Department, Lille University Hospital, Lille, France.
Cortot A; Gastroenterology and Hepatology Department, Lille University Hospital, Lille, France.
Zerbib P; Colorectal Surgery Department, Lille University Hospital, Lille, France.
Blanc P; Gastroenterology and Hepatology Department, Montpellier University Hospital, Montpellier, France.
Desreumaux P; Gastroenterology and Hepatology Department, Lille University Hospital, Lille, France.; Lille Inflammation Research International Center, Université Lille, CHRU de Lille, France.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Peyrin-Biroulet L; Gastroenterology Department, Nancy University Hospital, Lorraine University, Vandoeuvre, France.
Pineton de Chambrun G; Gastroenterology and Hepatology Department, Lille University Hospital, Lille, France.; Gastroenterology and Hepatology Department, Montpellier University Hospital, Montpellier, France.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2017 Mar 01; Vol. 11 (3), pp. 281-288.
Typ publikacji :
Journal Article
MeSH Terms :
Adalimumab/*therapeutic use
Crohn Disease/*prevention & control
Crohn Disease/*surgery
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adolescent ; Adult ; Colonoscopy ; Crohn Disease/diagnostic imaging ; Female ; Humans ; Male ; Postoperative Period ; Preoperative Period ; Recurrence ; Retrospective Studies ; Risk Factors ; Secondary Prevention ; Smoking/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids.
Autorzy :
Narula N; Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada.
Marshall JK; Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada.
Colombel JF; Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Leontiadis GI; Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada.
Williams JG; School of Medicine, Swansea University, Singleton Park, Swansea, UK.
Muqtadir Z; Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada.
Reinisch W; Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło :
The American journal of gastroenterology [Am J Gastroenterol] 2016 Apr; Vol. 111 (4), pp. 477-91. Date of Electronic Publication: 2016 Feb 09.
Typ publikacji :
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms :
Colitis, Ulcerative/*drug therapy
Cyclosporine/*therapeutic use
Gastrointestinal Agents/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Infliximab/*therapeutic use
Humans ; Steroids/therapeutic use
Czasopismo naukowe
Tytuł :
Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
Autorzy :
Fumery M; Gastroenterology Unit, Amiens University and Hospital, Université de Picardie Jules Verne, Amiens †Pediatric Unit, Jeanne de Flandre Hospital ‡Epimad Registry, EA 2694, Biostatistic Unit, Université Lille Nord de France §Pediatric Unit, St Vincent Hospital, Lille ||Pediatric Unit, Rouen University and Hospital ¶Gastroenterology Unit, Rouen University and Hospital, Rouen, France #Icahn School of Medicine at Mount Sinai, New York, NY **Gastroenterology Unit, Inserm U954, Université de Lorraine, Nancy ††EPIMAD Registry, EA 2694, Biostatistic Unit Université Lille Nord de France, Lille, France.
Jacob A
Sarter H
Michaud L
Spyckerelle C
Mouterde O
Savoye G
Colombel JF
Peyrin-Biroulet L
Gower-Rousseau C
Turck D
Pokaż więcej
Corporate Authors :
EPIMAD Group
Źródło :
Journal of pediatric gastroenterology and nutrition [J Pediatr Gastroenterol Nutr] 2015 Jun; Vol. 60 (6), pp. 744-8.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adalimumab/*therapeutic use
Crohn Disease/*drug therapy
Crohn Disease/*physiopathology
Infliximab/*administration & dosage
Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Adolescent ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; C-Reactive Protein/analysis ; Child ; Child Development/drug effects ; Crohn Disease/blood ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Infliximab/therapeutic use ; Male ; Nutritional Status/drug effects ; Orosomucoid/analysis ; Remission Induction/methods ; Retrospective Studies ; Time Factors ; Treatment Failure ; Treatment Outcome
SCR Disease Name :
Pediatric Crohn's disease
Czasopismo naukowe
Tytuł :
Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.
Autorzy :
Ternant D; Université François Rabelais de Tours, CNRS UMR 7292, 2 Boulevard Tonnellé, 37044, Tours, CEDEX, France, .
Berkane Z
Picon L
Gouilleux-Gruart V
Colombel JF
Allez M
Louis E
Paintaud G
Pokaż więcej
Źródło :
Clinical pharmacokinetics [Clin Pharmacokinet] 2015 May; Vol. 54 (5), pp. 551-62.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Crohn Disease/*drug therapy
Crohn Disease/*metabolism
Inflammation/*metabolism
Infliximab/*pharmacokinetics
Receptors, IgG/*genetics
Receptors, IgG/*metabolism
Adult ; C-Reactive Protein/metabolism ; Cohort Studies ; Crohn Disease/genetics ; Crohn Disease/surgery ; Female ; Genotype ; Humans ; Inflammation/genetics ; Male ; Multicenter Studies as Topic ; Polymorphism, Single Nucleotide ; Prospective Studies ; Recurrence
Czasopismo naukowe
Tytuł :
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
Autorzy :
Bouguen G; Division of Gastroenterology, University of California San Diego, La Jolla, California; †Service des Maladie de l'Appareil Digestif et INSERM U991, Centre Hospitalier Universitaire Pontchaillou et université de Rennes 1, Rennes, France; ‡Digestive Disease Associates, Gainesville, Florida; §Department of Medical Affairs, Janssen Biotech Inc., Horsham, Pennsylvania; ‖Department of Gastroenterology, Icahn Medical School at Mount Sinai, New York, New York; ¶Department of Gastroenterology, Academic Medical Center, Amsterdam, the Netherlands; **Imelda ziekenhuis, Bonheiden, Belgium; ††Department of Gastroenterology, Evangelismos Hospital, Athens, Greece; ‡‡Department of Medicine, ShaareZedek Medical Center, Jerusalem, Israel; §§Department of Internal Medicine III, University Vienna, Vienna, Austria; ‖‖Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; and ¶¶Departments of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
Sninsky C
Tang KL
Colombel JF
DʼHaens G
Kornbluth A
Mantzaris GJ
Rachmilewitz D
Reinisch W
Rutgeerts P
Molenda M
Jannekevan der Woude C
Sandborn WJ
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2015 Mar; Vol. 21 (3), pp. 606-14.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Azathioprine/*therapeutic use
Crohn Disease/*drug therapy
Erythrocyte Indices/*drug effects
Erythrocytes/*drug effects
Infliximab/*therapeutic use
Mucous Membrane/*drug effects
Wound Healing/*drug effects
Adult ; Biomarkers/analysis ; Crohn Disease/pathology ; Double-Blind Method ; Drug Therapy, Combination ; Erythrocytes/pathology ; Female ; Gastrointestinal Agents/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Mucous Membrane/pathology ; Prognosis
Czasopismo naukowe
Tytuł :
High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
Autorzy :
Hendler SA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cohen BL; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sands BE; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mayer L; Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Agarwal S; Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2015 Mar; Vol. 9 (3), pp. 266-75. Date of Electronic Publication: 2014 Dec 24.
Typ publikacji :
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Crohn Disease/*drug therapy
Gastrointestinal Agents/*administration & dosage
Infliximab/*administration & dosage
Adolescent ; Adult ; Drug Administration Schedule ; Female ; Gastrointestinal Agents/therapeutic use ; Humans ; Infliximab/therapeutic use ; Male ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies